Altimmune, Inc. Files 8-K with Regulatory Updates

Ticker: ALT · Form: 8-K · Filed: Dec 19, 2025 · CIK: 1326190

Altimmune, Inc. 8-K Filing Summary
FieldDetail
CompanyAltimmune, Inc. (ALT)
Form Type8-K
Filed DateDec 19, 2025
Risk Levellow
Pages6
Reading Time7 min
Key Dollar Amounts$0.0001, $200.0 million, $54.6 million
Sentimentneutral

Sentiment: neutral

Topics: 8-K, regulatory-filing, disclosure

TL;DR

Altimmune filed an 8-K on 12/19/25 covering Reg FD, other events, and financials.

AI Summary

Altimmune, Inc. filed an 8-K on December 19, 2025, reporting on various events. The filing includes information related to Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. The company, formerly known as Pharmathene, Inc. and Healthcare Acquisition Corp, is incorporated in Delaware and headquartered in Gaithersburg, Maryland.

Why It Matters

This 8-K filing provides important updates and disclosures from Altimmune, Inc. to investors and the public regarding company events and financial information.

Risk Assessment

Risk Level: low — This filing is a routine 8-K report and does not appear to contain any specific negative or positive material events that would inherently increase risk.

Key Players & Entities

  • Altimmune, Inc. (company) — Registrant
  • December 19, 2025 (date) — Date of earliest event reported
  • Pharmathene, Inc. (company) — Former company name
  • Healthcare Acquisition Corp (company) — Former company name
  • Gaithersburg, Maryland (location) — Company headquarters

FAQ

What specific events are being disclosed under Regulation FD?

The filing indicates a Regulation FD Disclosure item, but the specific details of the disclosure are not provided in the provided text snippet.

What are the 'Other Events' being reported by Altimmune, Inc.?

The filing lists 'Other Events' as an item, but the specific nature of these events is not detailed in the provided text.

What financial statements and exhibits are included with this 8-K filing?

The filing states that 'Financial Statements and Exhibits' are included, but the content of these documents is not specified in the provided text.

When was Altimmune, Inc. incorporated and in which jurisdiction?

Altimmune, Inc. was incorporated in Delaware, as indicated by the filing.

What is the business address and phone number for Altimmune, Inc.?

The business address is 910 Clopper Road, Suite 201S, Gaithersburg, Maryland 20878, and the business phone number is 2406541450.

Filing Stats: 1,746 words · 7 min read · ~6 pages · Grade level 10.3 · Accepted 2025-12-19 06:30:43

Key Financial Figures

  • $0.0001 — ch registered Common stock, par value $0.0001 per share ALT The NASDAQ Global Mar
  • $200.0 million — ng an aggregate offering price of up to $200.0 million through the sales agent (the "November
  • $54.6 million — stock for net proceeds of approximately $54.6 million pursuant to the February 2025 ATM Progr

Filing Documents

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release issued by Altimmune, Inc. on December 19, 2025. 99.2 Phase 2b IMPACT Study slide presentation of Altimmune, Inc. 104 Cover Page Interactive Data File (embedded within Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 19, 2025 ALTIMMUNE, INC. By: /s/ Gregory Weaver Name: Gregory Weaver Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.